ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 135 filers reported holding ASCENDIS PHARMA A/S in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $67,424,000 | -99.9% | 700,000 | +40.0% | 6.19% | -3.1% |
| Q2 2019 | $57,575,000,000 | +79438.9% | 500,000 | -18.7% | 6.39% | -10.8% |
| Q1 2019 | $72,386,000 | +7031.6% | 615,000 | +703.8% | 7.16% | +2362.2% |
| Q2 2016 | $1,015,000 | -81.6% | 76,511 | -75.4% | 0.29% | -86.4% |
| Q2 2015 | $5,502,000 | -6.7% | 311,222 | -8.4% | 2.14% | -17.3% |
| Q1 2015 | $5,896,000 | – | 339,863 | – | 2.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |